Biopharma Layoffs Fall to Lowest Level Since 2024 in Q3
BioSpace's Q3 tally shows biopharma layoffs fell sharply from a year earlier, with 56% fewer companies and 90% fewer workers affected. The quarter's 27 companies and 2,568 affected employees were the lowest since tracking began in 2024. Big Pharma accounted for more than 1,800 of those potential cuts, including Bristol Myers Squibb's 265 planned layoffs in Princeton, New Jersey.
The 27 companies and 2,568 affected workers marked the smallest quarterly totals since BioSpace began tracking in 2024. Company-level reductions have fallen every quarter since early 2025, staying below 30 in both Q2 and Q3 2026.
Eight large drugmakers accounted for 1,845 cuts. Bristol Myers Squibb plans 265 Princeton layoffs from December 2026 to May 2027. GSK’s vaccine manufacturing consolidation could eliminate about 650 German jobs, while Johnson & Johnson is cutting 87 in New Brunswick after 56 earlier New Jersey reductions.
The slowdown may ease immediate job-loss pressure for biopharma workers and their communities, especially in New Jersey, where several large employers are still trimming roles. Fewer layoffs could stabilize local hiring and spending, though the affected employees and families still face income disruption and retraining needs. If the trend continues, it may signal a less contractionary period for the sector, but quarterly figures can shift and do not guarantee sustained job security.